Skip to main content
US EQUITIES PRE-MARKET CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
MS

MSLEStockSatellos Bioscience Inc.

Nasdaq Global Market · Healthcare · CA

$5.94 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment MSLE's does — no target price to set, unlike a price alert.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol
0 of 3 pass our own screen — 4 of 7 could not be computed
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 4 timeframes bullish · 76.5% aligned
VWAPPrice below VWAP ($6.49)
VolumeRelative volume 4.9× the 20-day average
Momentum10-day rate of change -8.2%
Market & analysts
Wall Street consensus
BUY
11 analysts
Price target
$24.17
+306.8% · 6 analysts
Institutional own.
50.1%
of shares
Momentum (10d)
-8.2%
rate of change
SMC grade
F · 34
76.5% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
F · 34
SMC grade — 76.5% timeframe alignment
-8.2%
Rate of change (10d)
BUY
Wall Street consensus (11)
$24.17
Price target (+306.8%) · 6 analysts
50.1%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2025-12-31. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $193.1M as of 2026-08-28.

Business activity: cleared (no excluded categories detected)

AAOIFI Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 2 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 30.00% Pass(30.0pp buffer)
Interest-bearing investments 14.35% 30.00% Pass(15.6pp buffer)
Usmani Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.00% Pass(33.0pp buffer)
Interest-bearing investments 86.90% 33.00% Fail(53.9pp over)
Non-liquid assets 13.10% at least 20.00% Fail(6.9pp below the floor)
MSCI Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 86.90% 33.33% Fail(53.6pp over)
FTSE Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 86.90% 33.33% Fail(53.6pp over)
Dow Jones Islamic Market Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 2 of 2 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.00% Pass(33.0pp buffer)
Cash + interest-bearing securities 12.93% 33.00% Pass(20.1pp buffer)
S&P Shariah Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 2 of 2 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.00% Pass(33.0pp buffer)
Cash + interest-bearing securities 16.11% 49.00% Pass(32.9pp buffer)
MSCI M-Series Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 2 of 2 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 16.11% 33.33% Pass(17.2pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Usmani (% of total assets)debt ratio 33.0pts
MSCI Islamic Index (% of total assets)debt ratio 33.3pts
FTSE Shariah Global Equity Index Series (% of total assets)debt ratio 33.3pts
Usmani (% of total assets)investments ratio 53.9pts
MSCI Islamic Index (% of total assets)cash and interest ratio 53.6pts
FTSE Shariah Global Equity Index Series (% of total assets)cash and interest ratio 53.6pts

The numbers the ratios are built from

Read from MSLE's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period not measured — —
Interest-bearing debtBorrowings — which definition was stored is not recorded $0 2025-12-31 no debt tag reported in 3+ years (treated as $0)
Cash and interest-bearing securitiesCash, equivalents and marketable securities $27.7M 2025-12-31 CashAndCashEquivalents, CurrentInvestments
Total assetsBalance sheet total $31.9M 2025-12-31 Assets
Market capDenominator for AAOIFI $193.1M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $7.7M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $8.8M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $0 2025-12-31 no interest-income tag reported in 3+ years (treated as $0)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2025-12-31. Income statement as of 2025-12-31. Screened 2026-08-28.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$31.9M
    Assets · balance sheet as of 2025-12-31
  • Interest-bearing debt$0
    no debt tag reported in 3+ years (treated as $0) · balance sheet as of 2025-12-31
  • Cash and interest-bearing securities$27.7M
    CashAndCashEquivalents, CurrentInvestments · balance sheet as of 2025-12-31
  • Interest income (non-permissible)$0
    no interest-income tag reported in 3+ years (treated as $0) · income statement as of 2025-12-31
  • Market cap$193.1M
    Market-data quote at screen time, 2026-08-28 · not a filing figure, so no link

What changed, and when

Verdict history for MSLE. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for MSLE has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Tracked investors holding MSLE
InvestorFirmPositionWeightAs of
Steven Cohen Point72 Asset Management $6M 0.0% 2026-09-30
Israel Englander Millennium Management $2M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

13.0111.169.307.455.592025-11-192026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
5.78
S2
5.95
S1
6.07
PIVOT
6.24
R1
6.36
R2
6.53
R3
6.65

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
4.85 – 7.55
±21.71% from 6.20, made 2026-11-18 · resolves 2026-11-25
STRONG SELL
from 19 indicators
78.7% of our last 25417 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.4% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)36.00NEUTRAL
Stochastic %K (14)0.00BUY
CCI (20)-140.20BUY
Williams %R (14)-100.00BUY
MACD (12,26,9)-0.00SELL
ROC (10)-8.19SELL
Momentum (10)-0.53SELL
EMA (10)6.51SELL
SMA (10)6.68SELL
EMA (20)6.71SELL
SMA (20)6.63SELL
EMA (30)6.93SELL
SMA (30)6.72SELL
EMA (50)7.34SELL
SMA (50)7.58SELL
EMA (100)7.78SELL
SMA (100)8.46SELL
EMA (200)7.87SELL
SMA (200)8.26SELL

About Satellos Bioscience Inc.

Healthcare · Biotechnology

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

satellos.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

No real edge — avoid

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 43
🕐 1H BULLISH 49
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-8.2%
Rate of change (10d)
4.9×
Volume vs its 20-day average
-0.33
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.